MARYELLEN FLEMING-PRICE: Open Payments
NPI 1114383213 · WHEATON, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$912 in 38 payments from 16 companies in 2025. Trend: 2023 $869 · 2024 $888 · 2025 $912
Food & beverage: $912
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $213 |
| Neurocrine BioSciences, Inc. | 5 | $119 |
| Alkermes, Inc. | 4 | $89 |
| Tris Pharma Inc | 4 | $77 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| ABBVIE INC. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Corium, LLC | 1 | $25 |
Products named: REXULTI, INGREZZA, ARISTADA, Dyanavel XR, VRAYLAR, CAPLYTA, Auvelity, UZEDY.
Industry payments across IL — which companies pay providers there.
